347850.KQ
347850.KQ
KR7347850000
D&D Pharmatech
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 65/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±100.4% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves approx. 1.7x as much as the broader market.

Beta (Market Relation)
1.73x
Above average
Volatility (3Y p.a.)
100.4% p.a.
Fallback
Max Drawdown (3Y)
-62.4%
Fallback
Sharpe Ratio
0.86
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -14.8%
3 Years 100.4% -62.4% 0.86 —
5 Years — — — —
10 Years — — — —

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
High market risk: Beta of 1.73 indicates above-average volatility compared to the broader market.
ende